Newer antidepressants for hot flashes - Should their efficacy still be up for debate?

Charles Lawrence Loprinzi, Debra L. Barton, Jeff A Sloan, Paul J. Novotny, Sherry Wolf

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVE: Newer antidepressants have been shown in clinical trials to reduce hot flashes, although not as well as do hormones. Nonetheless, a recently published meta-analysis and subsequent editorial raised doubts with regard to the utility of newer antidepressants for treating hot flashes. Concerns about the lack of efficacy of newer antidepressants on hot flashes were based in large part on results of two placebo-controlled, double-blind trials, one evaluating venlafaxine and the other individually evaluating both fluoxetine and citalopram. These two studies have repeatedly been put forward as evidence that newer antidepressants are not definitively proven to reduce hot flashes. DESIGN: Raw data from these two randomized, placebo-controlled trials evaluating second-generation antidepressants for hot flashes were obtained. These data and subsequent study conclusions are evaluated and discussed in the context of other published trial data regarding the use of newer antidepressants for treating hot flashes. RESULTS: Examination of the raw data from these two trials revealed that neither employed a baseline period of hot flash determination against which to calculate changes over time from baseline. CONCLUSIONS: Recognition that these two trials cannot be used to look at hot flash frequency or score changes from baseline limits their ability to inform the efficacy literature about the use of newer antidepressants for hot flash reduction.

Original languageEnglish (US)
Pages (from-to)184-187
Number of pages4
JournalMenopause
Volume16
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Hot Flashes
Antidepressive Agents
Placebos
Citalopram
Fluoxetine
Meta-Analysis
Randomized Controlled Trials
Clinical Trials
Hormones

Keywords

  • Hot flashes
  • Second-generation antidepressants

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Medicine(all)

Cite this

Newer antidepressants for hot flashes - Should their efficacy still be up for debate? / Loprinzi, Charles Lawrence; Barton, Debra L.; Sloan, Jeff A; Novotny, Paul J.; Wolf, Sherry.

In: Menopause, Vol. 16, No. 1, 01.2009, p. 184-187.

Research output: Contribution to journalArticle

Loprinzi, Charles Lawrence ; Barton, Debra L. ; Sloan, Jeff A ; Novotny, Paul J. ; Wolf, Sherry. / Newer antidepressants for hot flashes - Should their efficacy still be up for debate?. In: Menopause. 2009 ; Vol. 16, No. 1. pp. 184-187.
@article{44755b7d3e10458b9ea5062db216b377,
title = "Newer antidepressants for hot flashes - Should their efficacy still be up for debate?",
abstract = "OBJECTIVE: Newer antidepressants have been shown in clinical trials to reduce hot flashes, although not as well as do hormones. Nonetheless, a recently published meta-analysis and subsequent editorial raised doubts with regard to the utility of newer antidepressants for treating hot flashes. Concerns about the lack of efficacy of newer antidepressants on hot flashes were based in large part on results of two placebo-controlled, double-blind trials, one evaluating venlafaxine and the other individually evaluating both fluoxetine and citalopram. These two studies have repeatedly been put forward as evidence that newer antidepressants are not definitively proven to reduce hot flashes. DESIGN: Raw data from these two randomized, placebo-controlled trials evaluating second-generation antidepressants for hot flashes were obtained. These data and subsequent study conclusions are evaluated and discussed in the context of other published trial data regarding the use of newer antidepressants for treating hot flashes. RESULTS: Examination of the raw data from these two trials revealed that neither employed a baseline period of hot flash determination against which to calculate changes over time from baseline. CONCLUSIONS: Recognition that these two trials cannot be used to look at hot flash frequency or score changes from baseline limits their ability to inform the efficacy literature about the use of newer antidepressants for hot flash reduction.",
keywords = "Hot flashes, Second-generation antidepressants",
author = "Loprinzi, {Charles Lawrence} and Barton, {Debra L.} and Sloan, {Jeff A} and Novotny, {Paul J.} and Sherry Wolf",
year = "2009",
month = "1",
doi = "10.1097/gme.0b013e31817dfd2b",
language = "English (US)",
volume = "16",
pages = "184--187",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Newer antidepressants for hot flashes - Should their efficacy still be up for debate?

AU - Loprinzi, Charles Lawrence

AU - Barton, Debra L.

AU - Sloan, Jeff A

AU - Novotny, Paul J.

AU - Wolf, Sherry

PY - 2009/1

Y1 - 2009/1

N2 - OBJECTIVE: Newer antidepressants have been shown in clinical trials to reduce hot flashes, although not as well as do hormones. Nonetheless, a recently published meta-analysis and subsequent editorial raised doubts with regard to the utility of newer antidepressants for treating hot flashes. Concerns about the lack of efficacy of newer antidepressants on hot flashes were based in large part on results of two placebo-controlled, double-blind trials, one evaluating venlafaxine and the other individually evaluating both fluoxetine and citalopram. These two studies have repeatedly been put forward as evidence that newer antidepressants are not definitively proven to reduce hot flashes. DESIGN: Raw data from these two randomized, placebo-controlled trials evaluating second-generation antidepressants for hot flashes were obtained. These data and subsequent study conclusions are evaluated and discussed in the context of other published trial data regarding the use of newer antidepressants for treating hot flashes. RESULTS: Examination of the raw data from these two trials revealed that neither employed a baseline period of hot flash determination against which to calculate changes over time from baseline. CONCLUSIONS: Recognition that these two trials cannot be used to look at hot flash frequency or score changes from baseline limits their ability to inform the efficacy literature about the use of newer antidepressants for hot flash reduction.

AB - OBJECTIVE: Newer antidepressants have been shown in clinical trials to reduce hot flashes, although not as well as do hormones. Nonetheless, a recently published meta-analysis and subsequent editorial raised doubts with regard to the utility of newer antidepressants for treating hot flashes. Concerns about the lack of efficacy of newer antidepressants on hot flashes were based in large part on results of two placebo-controlled, double-blind trials, one evaluating venlafaxine and the other individually evaluating both fluoxetine and citalopram. These two studies have repeatedly been put forward as evidence that newer antidepressants are not definitively proven to reduce hot flashes. DESIGN: Raw data from these two randomized, placebo-controlled trials evaluating second-generation antidepressants for hot flashes were obtained. These data and subsequent study conclusions are evaluated and discussed in the context of other published trial data regarding the use of newer antidepressants for treating hot flashes. RESULTS: Examination of the raw data from these two trials revealed that neither employed a baseline period of hot flash determination against which to calculate changes over time from baseline. CONCLUSIONS: Recognition that these two trials cannot be used to look at hot flash frequency or score changes from baseline limits their ability to inform the efficacy literature about the use of newer antidepressants for hot flash reduction.

KW - Hot flashes

KW - Second-generation antidepressants

UR - http://www.scopus.com/inward/record.url?scp=64049101827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64049101827&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e31817dfd2b

DO - 10.1097/gme.0b013e31817dfd2b

M3 - Article

VL - 16

SP - 184

EP - 187

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 1

ER -